Skip to main content
SearchLoginLogin or Signup

Reviews of "Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19"

Reviewers: Arthur Reingold (UC Berkeley) | 📘📘📘📘📘 • Jorge Salinas (Stanford University) | 📗📗📗📗◻️

Published onNov 06, 2021
Reviews of "Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19"
key-enterThis Pub is a Review of
Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19

AbstractBACKGROUNDFollowing administration to persons 60+ years of age, the booster vaccination campaign in Israel was gradually expanded to younger age groups who received a second dose >5 months earlier. We study the booster effect on COVID-19 outcomes.METHODSWe extracted data for the period July 30, 2021 to October 6, 2021 from the Israeli Ministry of Health database regarding 4,621,836 persons. We compared confirmed Covid-19 infections, severe illness, and death of those who received a booster ≥12 days earlier (booster group) with a nonbooster group. In a secondary analysis, we compared the rates 3-7 days with ≥12 days after receiving the booster dose. We used Poisson regressions to estimate rate ratios after adjusting for possible confounding factors.RESULTSConfirmed infection rates were ≈10-fold lower in the booster versus nonbooster group (ranging 8.8-17.6 across five age groups) and 4.8-11.2 fold lower in the secondary analysis. Severe illness rates in the primary and secondary analysis were 18.7-fold (95% CI, 15.7-22.4) and 6.5-fold (95% CI, 5.1-8.3) lower for ages 60+, and 22.0-fold (95% CI, 10.3-47.0) and 3.2-fold (95% CI, 1.1-9.6) lower for ages 40-60. For ages 60+, COVID-19 associated death rates were 14.7-fold (95% CI, 9.4-23.1) lower in the primary analysis and 4.8-fold (95% CI, 2.8-8.2) lower in the secondary analysis.CONCLUSIONSAcross all age groups, rates of confirmed infection and severe illness were substantially lower among those who received a booster dose of the BNT162b2 vaccine.

To read the original manuscript, click the link above.

Summary of Reviews: This paper claims that compared to people who only received two doses of the Pfizer vaccine, those who additionally received the booster dose are less likely to have SARS CoV 2 infection, severe illness, and death. Both reviewers agree on the robustness of the study methods.

Reviewer 1 (Arthur Reingold) | 📘📘📘📘📘

Reviewer 2 (Jorge Salinas) | 📗📗📗📗◻️

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below. 

No comments here
Why not start the discussion?